Pilocarpine

Pilocarpine

SCHEMBL725541

CC[C@H]1C(=O)OC[C@@H]1Cc1cncn1C.Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1CHRM3

The experimentally established mechanism targets of Pilocarpine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 2/20 0.97
CHRM3 known ✓ P20309 2/20 0.97
LMNA P02545 3/20 1.00
KDM4E B2RXH2 1/20 1.00
MAPT P10636 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
CYP3A4 P08684 3/20 0.97
CHRM5 P08912 3/20 0.97
CHRM4 P08173 2/20 0.97
CYP2C9 P11712 2/20 0.97
CHRM2 P08172 1/20 0.97
CYP2A6 P11509 1/20 0.97
CNR1 P21554 1/20 0.97
HTR2A P28223 1/20 0.97
CYP2A13 Q16696 1/20 0.97
MEN1 O00255 1/20 0.97
USP2 O75604 1/20 0.97
TP53 P04637 1/20 0.97
CYP1A2 P05177 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pilocarpine SCHEMBL41427 1.00 LMNA (1.00) LMNAKDM4EMAPTBLMPMP22
Pilocarpine SCHEMBL8370186 1.00 LMNA (1.00) LMNAKDM4EMAPTBLMPMP22
Pilocarpine SCHEMBL7076217 1.00 LMNA (1.00) LMNAKDM4EMAPTBLMPMP22
Pilocarpine SCHEMBL5504377 1.00 LMNA (1.00) LMNAKDM4EMAPTBLMPMP22
Pilocarpine SCHEMBL188019 0.99 LMNA (1.00) LMNAKDM4EMAPTBLMPMP22
Pilocarpine SCHEMBL15146 0.99 LMNA (1.00) LMNAKDM4EMAPTBLMPMP22
Pilocarpine SCHEMBL41890 0.99 LMNA (1.00) LMNAKDM4EMAPTBLMPMP22
Pilocarpine SCHEMBL9213198 0.99 LMNA (1.00) LMNAKDM4EMAPTBLMPMP22
Pilocarpine SCHEMBL678045 0.99 LMNA (1.00) LMNAKDM4EMAPTBLMPMP22
Pilocarpine SCHEMBL3078492 0.99 LMNA (1.00) LMNAKDM4EMAPTBLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1480677-B8 COMPOSITION FOR STABILIZING HYALURONIC ACID CARL ZEISS MEDITEC SAS (FR) 2012-05-23 EP claimed
EP-1480677-B1 COMPOSITION FOR STABILIZING HYALURONIC ACID IOLTECH (FR) 2012-02-29 EP claimed
EP-0822822-A4 CONTROLLED RELEASE OF MIOTIC AND MYDRIATIC DRUGS IN THE ANTERIOR CHAMBER IOLTECH (FR) 2006-01-11 EP claimed
EP-1027015-B1 CONTROLLED RELEASE OF PHARMACEUTICALS IN THE ANTERIOR CHAMBER OF THE EYE IOLTECH (FR) 2005-02-09 EP claimed
EP-1480677-A2 COMPOSITION FOR STABILIZING HYALURONIC ACID IOLTECH (FR) 2004-12-01 EP claimed
US-20030133986-A1 Compositions for stabilizing poly (carboxylic acids) TSAO FU-PAO (US) 2003-07-17 US claimed
WO-2003043660-A2 COMPOSITION FOR STABILIZING HYALURONIC ACID NOVARTIS AG (CH) 2003-05-30 WO claimed
US-5972326-A Controlled release of pharmaceuticals in the anterior chamber of the eye IOLTECH (FR) 1999-10-26 US claimed
US-5759532-A Controlled release of miotic and myriatic drugs in the anterior chamber IOLTECH (FR) 1998-06-02 US claimed
EP-0822822-A1 CONTROLLED RELEASE OF MIOTIC AND MYDRIATIC DRUGS IN THE ANTERIOR CHAMBER IOLTECH (FR) 1998-02-11 EP claimed
WO-1996032951-A1 CONTROLLED RELEASE OF MIOTIC AND MYDRIATIC DRUGS IN THE ANTERIOR CHAMBER GALIN MILES A (US) 1996-10-24 WO claimed
US-20150174112-A1 COMPOSITIONS FOR TREATING FRAGILE X AND OTHER DISORDERS METHODS OF USE THEREOF, AND SCREENING FOR COMPOUNDS FOR FRAGILE X AND OTHER DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-06-25 US disclosed
EP-1480677-B8 COMPOSITION FOR STABILIZING HYALURONIC ACID CARL ZEISS MEDITEC SAS (FR) 2012-05-23 EP disclosed
EP-1480677-B1 COMPOSITION FOR STABILIZING HYALURONIC ACID IOLTECH (FR) 2012-02-29 EP disclosed
US-20080312279-A1 Compositions for Treating Fragile X and Other Disorders Methods of Use Thereof, and Screening for Compounds for Fragile X and Other Disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-18 US disclosed
US-5766580-A Controlled release of miotic and mydriatic drugs in the anterior chamber IOLTECH (FR) 1998-06-16 US disclosed
US-5759532-A Controlled release of miotic and myriatic drugs in the anterior chamber IOLTECH (FR) 1998-06-02 US disclosed
EP-0822822-A1 CONTROLLED RELEASE OF MIOTIC AND MYDRIATIC DRUGS IN THE ANTERIOR CHAMBER IOLTECH (FR) 1998-02-11 EP disclosed
US-5612027-A Controlled release of miotic and mydriatic drugs in the anterior chamber IOLTECH (FR) 1997-03-18 US disclosed
WO-1996032951-A1 CONTROLLED RELEASE OF MIOTIC AND MYDRIATIC DRUGS IN THE ANTERIOR CHAMBER GALIN MILES A (US) 1996-10-24 WO disclosed